[HTML] thelancet.com

[HTML][HTML] Effectiveness of XBB. 1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA

DY Lin, S Huang, A Milinovich, A Duggal… - The Lancet Infectious …, 2024 - thelancet.com
In the fall of 2023, the US Food and Drug Administration (FDA) authorised the use of the
updated Moderna (Sept 11), Pfizer-BioNTech (Sept 11), and Novavax (Oct 3) COVID-19 …
相关文章

[引用][C] Effectiveness of XBB. 1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA

DY Lin, S Huang, A Milinovich, A Duggal… - The Lancet Infectious …, 2024 - thelancet.com
(Sept 11), Pfizer-BioNTech (Sept 11), and Novavax (Oct 3) COVID-19 vaccines containing a
monovalent component of the XBB. 1.5 variant “to provide better protection against serious …

[引用][C] Effectiveness of XBB. 1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA.

DY Lin, S Huang, A Milinovich, A Duggal… - The Lancet. Infectious …, 2024 - europepmc.org
Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron
infection in the USA. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

[引用][C] Effectiveness of XBB. 1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA

DY Lin, S Huang, A Milinovich… - The Lancet …, 2024 - pubmed.ncbi.nlm.nih.gov
Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron
infection in the USA Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe …